New Video and Slides - Treat or No Treat:Treatment Decisions for CHB

[Guest guest]

>

> Release Date: December 3, 2010

>

> Expiration Date: December 3, 2011

>

> [http://www.hivandhepatitis.com/cme/2010/healthmatters/aasld/case2.gif]

>

> New Video and Slides - Treat or No Treat:

> A Case-based Discussion Considering

> Evidence and Expert Insights

> in Treatment Decisions for CHB

>

>

[http://www.hivandhepatitis.com/cme/2010/healthmatters/aasld/video/images/button\

1b.gif]

>

>

> Faculty

>

> Program Chair

> Eugene R. Schiff, MD, MACP, FRCP, MACG, AGAF

> Leonard Professor of Medicine

> Director, Schiff Liver Institute

> Director, Center for Liver Diseases

> Division of Hepatology

> Miami, FL

>

>

> Mark Sulkowski, MD

> Associate Professor of Medicine

> Medical Director, Viral Hepatitis Center

> s Hopkins University School of Medicine

> Baltimore, MD

>

> Gish, MD

> Professor of Clinical Medicine

> Co-director, CHAT

> Chief of Clinical Hepatology

> University of California,

> San Diego Medical Center

> San Diego, CA

>

>

>

> Tram T. Tran, MD

> Associate Professor of Medicine

> Geffen UCLA School of Medicine

> Medical Director

> Liver Transplant Program

> Cedars-Sinai Medical Center

> Los Angeles, CA

>

> PROGRAM OVERVIEW

>

> Chronic hepatitis B (CHB) continues to be a significantly untreated

> disease in the United States. Two-thirds of the estimated 1.25 million

> hepatitis B carriers in the United States do not know they are infected

> and are unlikely to discover their status until they show signs of

> potentially life-threatening illnesses. rs of hepatitis B virus

> (HBV) are at increased risk for developing cirrhosis, hepatic

> decompensation, and hepatocellular carcinoma (HCC), with 15% to 40%

> developing these serious hepatic complications in their lifetime. There

> is an urgent need to screen, diagnose, and treat CHB to prevent further

> spread and reduce morbidity and mortality associated with CHB.

>

> During this case-based video and slide presentation, experts will

> discuss the significant advances that have been made in the past 5

> years in our understanding of the natural history of hepatitis B and

> the management of patients with CHB. In addition, the 2009 American

> Association for the Study of Liver Diseases (AASLD) Practice Guidelines

> and the most recent European Association for Study of the Liver (EASL)

> Clinical Practice Guidelines will be examined. Pregnancy in the patient

> with CHB also presents the provider with a unique set of management

> challenges which will be addressed by the Faculty. These include

> maternal and fetal effects of hepatitis B, effects of pregnancy itself

> on the course of hepatitis B infection and its complications, treatment

> of hepatitis B during pregnancy, and prevention of perinatal infection.

> In addition, patients with hepatitis B undergoing immunosuppressive or

> cancer chemotherapy present a different set of challenges for the

> provider, including prophylactic antiviral therapy and timing of

> initiation of chemotherapy. These challenges, among others, will be

> addressed in terms of the 2009 AASLD Practice Guidelines and the 2010

> American Society of Clinical Oncology Clinical Practice Guidelines.

>

>

> TARGET AUDIENCE

>

> This activity is designed for hepatologists and gastroenterologists who

> treat patients with CHB.

> EDUCATIONAL OBJECTIVES

>

> Upon completing this program, participants will be better able to:

> • Integrate the 2009 AASLD Practice Guidelines into clinical

> practice with respect to screening at-risk patients, treatment timing,

> selection of agents and duration of treatment

> • Develop treatment strategies for the management of pregnant

> women with CHB and for the prevention of perinatal infection in

> newborns

> • Develop management strategies for HBV carriers undergoing

> immunosuppressive or cytotoxic therapy

>

> PHYSICIAN CONTINUING MEDICAL EDUCATION

>

> Accreditation Statement

> This activity has been planned and implemented in accordance with the

> Essential Areas and policies of the Accreditation Council for

> Continuing Medical Education (ACCME) through the joint sponsorship of

> Postgraduate Institute for Medicine (PIM) and HealthmattersCME. PIM is

> accredited by the ACCME to provide continuing medical education for

> physicians.

>

> Credit Designation

> Postgraduate Institute for Medicine designates this educational

> activity for a maximum of 1.75 AMA PRA Category 1 Credit(s)™.

> Physicians should only claim credit commensurate with the extent of

> their participation in the activity.

>

>

> DISCLOSURE OF CONFLICTS OF INTEREST

>

> Postgraduate Institute for Medicine (PIM) requires instructors,

> planners, managers, and other individuals who are in a position to

> control the content of this activity to disclose any real or apparent

> conflict of interest they may have related to the content of this

> activity. All identified conflicts of interest are thoroughly vetted by

> PIM for fair balance, scientific objectivity of studies mentioned in

> the materials or used as the basis for content, and appropriateness of

> patient care recommendations.

> METHOD OF PARTICIPATION/HOW TO OBTAIN CME CREDIT

>

> There are no fees for participating and receiving CME credit for this

> activity. During the period December 3, 2010 through December 3, 2011,

> participants must (1) read the learning objectives and faculty

> disclosures; (2) study the educational activity; (3) complete the

> posttest by going to

> http://www.cmeuniversity.com

> to register or login, click on " Find Post-tests by Course " on the

> navigation menu, select Course 7585, and recording the best answer to

> each question; and (4) complete the evaluation form and credit request.

> A statement of credit will be issued only upon receipt of a completed

> activity evaluation form and a completed posttest with a score of 70%

> or better.

> Media

>

> Internet Activity

> This webcast requires a broadband Internet connection, Flash Player 8

> or greater, (optional) sound card and speakers for audio.

>

>

[http://www.hivandhepatitis.com/cme/2010/healthmatters/aasld/video/images/button\

1a.gif]

>

>

[http://www.hivandhepatitis.com/cme/2010/healthmatters/aasld/video/images/pim.gi\

f]

>

> This activity is jointly sponsored by Postgraduate Institute for

> Medicine and HealthmattersCME.

>

>

[http://www.hivandhepatitis.com/cme/2010/healthmatters/aasld/video/images/gilead\

..gif]

>

> This activity is supported by an independent educational grant from

> Gilead Sciences Medical Affairs.

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

>

> Email Marketing by

> [http://img.constantcontact.com/letters/images/cc-logo-color-sm.gif]

>

> HIVandHepatitis.com | P.O. Box 2010 | San Francisco | CA | 94114

>

>